The Top 5 Biosimilars Articles for the Week of June 25
Here are the top 5 biosimilars articles for the week of June 25.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 25.
Number 5: A study presented at the annual European Congress of Rheumatology found that 80% of 80 patients with rheumatic disease were willing to switch to biosimilar etanercept, and switching did not affect efficacy.
Number 4: During the American Conference Institute’s Summit on Biosimilars, experts from BIO and PhRMA provided an overview of recent policy and legislative updates in biosimilars.
Number 3: Last week, the FDA withdrew a draft guidance document on statistical approaches to evaluate analytical similarity of biosimilars after the consideration of public comments.
Number 2: A recent study has found that disease activity assessment guidelines for patients with rheumatoid arthritis have not been well evaluated in the United States.
Number 1: The American Medical Association has announced that after analyzing the proposed $69 billion dollar merger between pharmacy benefit manager CVS Health and insurer Aetna, the organization is calling for regulators to block the transaction.
To read all of these articles and more, visit centerforbiosimilars.com.
Recent Findings Highlight Need for Policy Changes for Biosimilars, Follow-on Biologics
